Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (10040)	11/3/2015 4:39:02 PM
From: tuck	Read Replies (1) \| Respond to of 12215

Not much human data floating around on Copanlisib, but there is this from last year's ASH: Copanlisib 2014 ASH Haven't tried to compare this to single agent data from INFI or TGTX yet. Without more data on the patient demographics, that may be hard. First blush and from memory, tox looks kind of similar to duvelasib. Would venture that TGTX has the best safety, but efficacy/safety ratio, dunno. ASH in a month. Should be seeing abstracts any day. Cheers, Tuck